• Mineralys Therapeutics highlighted a Dec. 22, 2026, PDUFA target date for lorundrostat in its corporate presentation.
• Lorundrostat delivered a placebo-adjusted systolic blood pressure reduction of 11.6 mmHg at six weeks with 50 mg dosing.
• The targeted U.S. market comprises 20 million patients with uncontrolled or resistant hypertension.
• Cash balance totaled $625 million as of Sept. 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.